7 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $170M | -$313000 | 0.0% | -185.3% | -$179M | — | $167M |
| 2024 | $227M | -$547000 | 0.0% | -246.5% | -$382M | — | $562M |
| 2023 | $251M | -$893000 | 0.0% | -343.8% | -$336M | — | $944M |
| 2022 | $478M | -$2M | 0.0% | -462.4% | -$304M | — | $1.3B |
| 2021 | $314M | -$2M | 0.0% | -582.6% | -$310M | — | $1.6B |
| 2020 | $77M | -$127M | 0.0% | -178.8% | -$194M | — | $381M |
| 2019 | $54M | -$119M | 0.0% | -132.1% | -$67M | — | $495M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $19M | -$83M | 84.1% | -366.5% | -$49M | — | $144M |
| Dec '25 | $33M | -$81M | 0.0% | -211.9% | -$48M | — | $167M |
| Sep '25 | $39M | -$81M | 0.0% | -231.8% | -$32M | — | $111M |
| Jun '25 | $50M | — | 0.0% | -132.1% | -$40M | — | $204M |
| Mar '25 | $38M | -$91M | 89.3% | -211.8% | -$59M | — | $312M |
| Dec '24 | $44M | -$108M | 0.0% | -236.3% | -$56M | — | $562M |
| Sep '24 | $89M | -$56M | 0.0% | -62.0% | -$119M | — | $616M |
| Jun '24 | $56M | -$217M | 0.0% | -396.7% | -$111M | — | $730M |
| Mar '24 | $38M | — | 0.0% | -469.1% | -$96M | — | $840M |
| Dec '23 | $35M | -$212M | 0.0% | -512.5% | -$61M | — | $944M |
| Sep '23 | $55M | -$303M | 0.0% | -516.7% | -$78M | — | $1.0B |
| Jun '23 | $81M | -$173M | 0.0% | -228.6% | -$87M | — | $1.1B |
| Mar '23 | $81M | -$205M | 0.0% | -267.3% | -$110M | — | $1.2B |
| Dec '22 | $98M | -$175M | 0.0% | -234.9% | -$130M | — | $1.3B |
| Sep '22 | $66M | -$670M | 0.0% | -986.4% | -$42M | — | $1.3B |
| Jun '22 | $145M | -$669M | 0.0% | -447.9% | -$109M | — | $1.4B |
| Mar '22 | $168M | -$591M | 0.0% | -401.0% | -$23M | — | $1.5B |
| Dec '21 | $148M | -$1.6B | 0.0% | -1134.5% | -$171M | — | $1.6B |
| Sep '21 | $78M | -$102M | 0.0% | -34.4% | -$11M | — | $1.7B |
| Jun '21 | $44M | -$54M | 0.0% | -137.4% | -$59M | — | $236M |
How the market has priced DNA against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Ginkgo Bioworks Holdings, Inc.'s revenue has grown 17.3% per year. These are computed facts, not advice.
As of FY2025, Ginkgo Bioworks Holdings, Inc. reported — of total debt against $167M of cash.
In FY2025, gross margin was —, operating margin -185.3%, and net margin -0.2%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.